[HTML][HTML] Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma

T Chen, L Liu, Y Zou, X Hu, W Zhang… - Cancer Biology & …, 2021 - ncbi.nlm.nih.gov
Objective: Natural extracts, including nobiletin, have been reported to enhance the efficacy
and sensitivity of chemotherapeutic drugs. However, whether and how nobiletin affects …

[HTML][HTML] Nobiletin Inhibits Cell Viability via the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells

D Wei, G Zhang, Z Zhu, Y Zheng, F Yan… - Frontiers in …, 2019 - frontiersin.org
Nobiletin is a polymethoxy flavonoid isolated from Citrus depressa and Citrus reticulata. It
has been reported that nobiletin can suppress tumors. We primarily explored the antitumor …

Nobiletin inhibits viability of human renal carcinoma cells via the JAK2/STAT3 and PI3K/Akt pathway

Z Xu, D Wu, D Fu, C Tang, J Ge, Z Zhang… - Cellular and Molecular …, 2020 - cellmolbiol.org
Nobiletin, a flavonoid found chiefly in oranges and lemons, has exhibited potential anti-
proliferative and pro-apoptotic activities in various types of cancers. However, the inhibitory …

[HTML][HTML] Nobiletin suppresses cholangiocarcinoma proliferation via inhibiting GSK3β

L You, J Lin, Z Yu, Y Qian, Y Bi, F Wang… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Background: Cholangiocarcinoma (CCA) is a type of hepatobiliary cancer characterized by
uncontrolled cell proliferation, with a poor prognosis and high mortality. Nobiletin (NBT) is a …

LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma

DF McDermott, A Peer, N Agarwal, MB Atkins… - The …, 2023 - academic.oup.com
Background Immunotherapy is a standard-of-care first-line treatment for advanced clear cell
renal cell carcinoma (ccRCC). However, many patients will develop resistance to first-line …

Telocinobufagin, a PLK1 suppressor that inhibits tumor growth and metastasis by modulating CDC25c and CTCF in HNSCC cells

J Li, R Ma, J Lv, Y Ren, Y Tan, H Wang, Z Wang… - Phytomedicine, 2024 - Elsevier
Background The high metastasis and mortality rates of Head and neck squamous cell
carcinoma (HNSCC) urgently require new treatment targets and drugs. A steroidal …

Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak. Bcl-xl complex

G Zhang, L Li, J Li, P Li, S Zeng, H Sun, E Li - Biochemical pharmacology, 2019 - Elsevier
Palbociclib is a Cdk4/6 inhibitor approved for metastatic estrogen receptor-positive breast
cancer. The drug is also under clinical evaluation for metastatic urothelial cancer and other …

[HTML][HTML] Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells

X Yu, F Liu, L Zeng, F He, R Zhang, S Yan… - Cellular Physiology and …, 2018 - karger.com
Background/Aims: As the most lethal urological cancers, renal cell carcinoma (RCC)
comprises a heterogeneous group of cancer with diverse genetic and molecular alterations …

[HTML][HTML] The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors

J Small, E Washburn, K Millington, J Zhu, SL Holder - Oncotarget, 2017 - ncbi.nlm.nih.gov
Multiple therapies currently exist for renal cell carcinoma, however, most do not result in cure
and the development of acquired resistance is the rule rather than the exception. CDK4/6 …

[HTML][HTML] The RBPJ/DAPK3/UBE3A signaling axis induces PBRM1 degradation to modulate the sensitivity of renal cell carcinoma to CDK4/6 inhibitors

W Liu, B Zhang, D Zhang, F Guo, K Ye, L Zhu… - Cell death & …, 2022 - nature.com
Renal cell carcinoma (RCC) is a kind of malignant tumor originating from the renal tubular
epithelium. Approximately 30% of patients with renal cancer are found to have metastasis …